Gallium Ga-68 gozetotide

DCTPepD ID  DCTPepD0020

Active Ingredients   Gallium Ga-68 gozetotide

Description  Gallium (Ga) 68 prostate-specific membrane antigen (PSMA)-11, or Ga-68 gozetotide, is a radiopharmaceutical agent used to identify and assess prostate-specific membrane antigen (PSMA)-positive lesions in adult men with prostate cancer during positron emission tomography (PET). In nearly all prostate cancers, malignant cells express a transmembrane protein called prostate-specific membrane antigen (PSMA). Ga-68 PSMA-11 is an imaging agent that binds PSMA during positron emission tomography: it emits positrons to indicate the presence of PSMA-positive prostate cancer lesions in patients with suspected prostate cancer or in patients who may have recurrent prostate cancer.

Synonyms  Ga-68 gozetotide; (68)Ga labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC; (68)Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC; (68)Ga-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC; (68)Gallium-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC; (68Ga)Glu-urea-Lys(Ahx)-HBED-CC; 68Ga-DKFZ-PSMA-11; 68Ga-HBED-CC-PSMA; 68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC; 68Ga-PSMA; 68Ga-PSMA-11; 68Ga-PSMA-HBED-CC; [68Ga] Prostate-specific Membrane Antigen 11; [68Ga]GaPSMA-11; Ga PSMA; Ga-68 labeled DKFZ-PSMA-11; Ga-68 labeled PSMA-11; GA-68 PSMA-11; Gallium Ga 68 Gozetotide; Gallium Ga 68 PSMA-11; Gallium Ga 68-labeled PSMA-11; Gallium-68 PSMA; Gallium-68 PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC; GaPSMA; PSMA-HBED-CC GA-68; Gallium Ga-68 gozetotide

Disease  Prostatic Neoplasms

Classification

  

Peptide and derivative Cancer Targeted Radioconjugates

Structure Information


Molecular Formula  C44H59GaN6O17

Molecular Weight  1011.9

Active Sequence  Not available

Sequence Length  Not available

Modification  Not available

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  (68Ga)gallium(3+) 3-(3-{[(2-{[(5-{2-[(5-{[(5S)-5-carboxy-5-({[(1S)-1,3-dicarboxypropyl]carbamoyl}amino)pentyl]carbamoyl}pentyl)carbamoyl]ethyl}-2-hydroxyphenyl)methyl](carboxylatomethyl)amino}ethyl)(carboxylatomethyl)amino]methyl}-4-hydroxyphenyl)propanoate

InChI  InChI=1S/C44H62N6O17.Ga/c51-34-13-8-28(22-30(34)24-49(26-40(59)60)20-21-50(27-41(61)62)25-31-23-29(9-14-35(31)52)11-16-38(55)56)10-15-37(54)46-18-4-1-2-7-36(53)45-19-5-3-6-32(42(63)64)47-44(67)48-33(43(65)66)12-17-39(57)58;/h8-9,13-14,22-23,32-33,51-52H,1-7,10-12,15-21,24-27H2,(H,45,53)(H,46,54)(H,55,56)(H,57,58)(H,59,60)(H,61,62)(H,63,64)(H,65,66)(H2,47,48,67);/q;+3/p-3/t32-,33-;/m0./s1/i;1-2

InChI_Key AEBYHKKMCWUMKX-LNTZDJBBSA-K

SMILES  O=C(CCC1=CC=C(C(CN(CC([O-])=O)CCN(CC2=CC(CCC(NCCCCCC(NCCCC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O)=O)=O)=CC=C2O)CC([O-])=O)=C1)O)[O-].[68Ga+3]

External Codes


PubChem CID  154572876

DrugBank Accession Number  DB16019

NCI Thesaurus Code  C118961  

UNII  ZJ0EKR6M10   GSRS

CAS  1906894-20-9



Drug approval


Drug indication
    Gallium Ga-68 gozetotide, or Gallium Ga-68 PSMA-11, is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in patients with suspected prostate cancer metastasis who are also candidates for initial surgical or radiation therapy. It is also indicated for patients with suspected prostate cancer recurrence based on elevated serum prostate-specific antigen (PSA) levels.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT03903419 Feasibility Study for the Realization of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT for Identification of Early Recurrence in Patients Treated With Radiotherapy for Glioblastoma Glioblastomas Not Applicable Diagnostic
NCT03675451 PSMA Imaging of Localized Prostate Cancer Prostate Cancer Phase 2 Diagnostic
NCT05214820 Clinical Assessment of the Therapeutic Potential of 177Lu-PSMA Endoradiotherapy for the Treatment of Upper Metastatic Gastric Cancers Using 68Ga-PSMA PET-based Dosimetry Upper Digestive Tract Cancer Phase 2 Diagnostic
NCT02918357 Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence Prostate Cancer Phase 2/3 Diagnostic
NCT02919111 Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients Prostate Cancer Phase 2/3 Diagnostic

    More clinical information is obtained from ClinicalTrials.gov.





DCTPep is developed by Dr.Zheng's team.